Cadwalader Advises Acorda Therapeutics on Merger Agreement to Acquire Civitas Therapeutics

Cadwalader is pleased to have advised Acorda Therapeutics, Inc., a leading biotechnology company, on its execution of a merger agreement to acquire Civitas Therapeutics, Inc., a privately-held biopharmaceutical company, for $525 million in an all cash transaction.

Acorda will obtain worldwide rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinson’s disease. The acquisition also includes rights to Civitas’ proprietary ARCUS™ pulmonary delivery technology and manufacturing facility with commercial-scale capabilities based in Chelsea, MA.

The Cadwalader team was led by Corporate Co-chairs Jim Woolery and Christopher Cox, and included partners Ira Schacter (Corporate), Greg Patti (Corporate), Linda Swartz (Tax), Dorothy Auth (IP) and Andrew Forman (Antitrust).

Source:  www.cadwalader.com